The role of the FKBP51–Hsp90 complex in Alzheimer’s disease: An emerging new drug target
Xavier Jeanne, Zsolt Török, László Vigh, Chrisostomos Prodromou · 2024
Read The role of the FKBP51–Hsp90 complex in Alzheimer’s disease: An emerging new drug target by Xavier Jeanne, Zsolt Török, László Vigh, Chrisostomos Prodromou (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11664163.txt.
Description
Xavier Jeanne and colleagues review a chaperone partnership that bends tau toward tangles, and the drug lead that breaks it up, in this paper from twenty twenty-four. Ageing unbalances the cell's protein-folding crews. One co-chaperone, FKBP51, rises with age and rises further in Alzheimer disease, where it partners with the chaperone Hsp90 to twist tau into its disease-prone form.
Twisted tau takes phosphate marks more readily and clumps. The authors' hypothesis places this partnership downstream of amyloid plaques: plaque damage induces FKBP51, which then unleashes tauopathy. Supporting the target, the complex's structure is now solved, and a small molecule, LA1011, was shown to disrupt it and to prevent neurodegeneration in Alzheimer-model mice. The review assembles the case for drugging the FKBP51-Hsp90 complex before tau's cascade starts.
Catalog record
| CREATOR | Xavier Jeanne, Zsolt Török, László Vigh, Chrisostomos Prodromou |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |